These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Nov 1, 2018Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients
– Biomarker data obtained from 41 transfusion dependent patients support ACVR1 mechanism of action for momelotinib's anemia benefit in myelofibrosis – – 34% of patients achieved RBC...
Oct 4, 2018Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"
Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology...
Aug 22, 2018
- Up to $15 million available in three $5 million tranches; additional $25 million potentially available - VANCOUVER, Aug. 22, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage...
Aug 22, 2018Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
- More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients - - Demonstrated meaningful anemia-related...
Aug 9, 2018
- SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and...